Researchers Develop Hierarchical DNA Nanoplatform for Selective Senescence Modulation

Researchers engineered a dual-gated DNA nanoplatform that selectively suppresses SASP in therapy-induced senescent tumor cells via NF-κB blockade and promotes M1 macrophage polarization in vivo.

A research team reported the development of Gal-lipo@S-CHA, a hierarchical DNA nanoplatform designed to selectively reprogram senescent cells and remodel the tumor immune microenvironment.

The platform achieves dual-layer selectivity: a β-galactosidase-responsive charge-reversal lipid carrier mediates preferential delivery to senescent cells, while subsequent intracellular sensing of tumor-associated markers GSH and microRNA-21 restricts activation to pathological senescent tumor cells.

Upon activation, the catalytic DNA circuit blocks NF-κB nuclear translocation via an assembled NF-κB decoy, suppressing the pro-tumorigenic senescence-associated secretory phenotype (SASP) at its upstream source.

In vivo experiments demonstrated that the platform enhanced natural killer (NK) cell infiltration and M1 macrophage polarization within the tumor microenvironment.

Therapy-induced senescence (TIS) can lead to tumor drug resistance and recurrence, driven by pro-tumorigenic SASP factors.

Targeting SASP at the upstream transcriptional level (such as NF-κB) rather than destroying senescent cells entirely represents an alternative approach to managing pathological senescence.

The dual-gating strategy addresses the lack of specificity that has historically limited the selective modulation of senescent tumor cells.

The development highlights the growing interest in highly selective, localized senescence-modulating technologies as an alternative to systemic senolytics.

Preclinical findings demonstrating the remodeling of the tumor immune microenvironment via macrophage polarization support the rationale for combining selective senescence therapies with immunomodulatory approaches.

Further preclinical evaluation of the Gal-lipo@S-CHA platform in diverse tumor models to assess safety, biodistribution, and long-term efficacy before potential clinical translation.